Diabetic Retinopathy and Ocular Melanoma: How Far We Are?
Source abstract
Abstract
Diabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Retinal Diseases and Treatments · Ocular Oncology and Treatments · Angiogenesis and VEGF in Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
Department of Biology and Environment, University of Trás-os-Montes e Alto Douro, UTAD, Quinta de Prados, 5000-801 Vila Real, Portugal
Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal
CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, and Institute of Nanoscience and Nanotechnology (IN2UB), Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
Networking Research Centre of Neurodegenerative Disease (CIBERNED), Instituto de Salud Juan Carlos III, C/Valderrebollo, 5, 28031 Madrid, Spain
Department of Endocrinology of S. João Hospital, Alameda Prof. Hernâni Monteiro, 4200–319 Porto, Portugal
Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy
References (100+)
Show source-provided references
1. Uveal melanoma: Physiopathology and new in situ-specific therapies10.1007/s00280-019-03860-z ↗
2. Assessment of flow dynamics in retinal and choroidal microcirculation10.1016/j.survophthal.2018.03.003 ↗
3. Willermain, F., Scifo, L., Weber, C., Caspers, L., Perret, J., and Delporte, C. (2018). Potential Interplay between Hyperosmolarity and Inflammation on Retinal Pigmented Epithelium in Pathogenesis of Diabetic Retinopathy. Int. J. Mol. Sci., 19.10.3390/ijms19041056 ↗
4. Fangueiro, J.F., Silva, A.M., Garcia, M.L., and Souto, E.B. (2014). Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur. J. Pharm. Biopharm.10.1016/j.ejpb.2014.12.023 ↗
5. Rübsam, A., Parikh, S., and Fort, P.E. (2018). Role of Inflammation in Diabetic Retinopathy. Int. J. Mol. Sci., 19.10.3390/ijms19040942 ↗
6. Origins and consequences of hyperosmolar stress in retinal pigmented epithelial cells10.3389/fphys.2014.00199 ↗
7. High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: Implications for diabetic retinopathy10.1186/s12933-016-0342-4 ↗
8. Intake of dietary salt and drinking water: Implications for the development of age-related macular degeneration
9. Mashayekhi, A., Schönbach, E., Shields, C.L., and Shields, J.A. (2015). Early Subclinical Macular Edema in Eyes with Uveal Melanoma: Association with Future Cystoid Macular Edema. Ophthalmology.10.1016/j.ophtha.2014.12.034 ↗
10. Circulating bone-marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes10.1111/j.1755-3768.2009.01700.x ↗
11. Hypoxia specific SDF-1 expression by retinal pigment epithelium initiates bone marrow-derived cells to participate in Choroidal neovascularization in a laser-induced mouse model10.3109/02713683.2011.593107 ↗
12. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy10.1073/pnas.0911661107 ↗
13. Cancer-associated retinopathy: A new mechanistic insight on vascular remodeling10.4161/cc.9.10.11521 ↗
14. Role of IL-8 induced angiogenesis in uveal melanoma10.1007/s10637-013-0005-1 ↗
15. Ocular melanoma: An overview of the current status
16. Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines
17. Ocular melanoma: What’s new?10.1097/CCO.0b013e32834ff069 ↗
18. Ocular diseases in metastatic cutaneous melanoma: Review of 108 consecutive patients in two German tertiary centers10.1007/s00417-013-2563-5 ↗
19. Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis10.1002/ijc.28625 ↗
20. Estimating prognosis for survival after treatment of choroidal melanoma10.1016/j.preteyeres.2011.05.003 ↗
21. A molecular revolution in uveal melanoma: Implications for patient care and targeted therapy10.1016/j.ophtha.2013.12.014 ↗
22. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification10.1158/1078-0432.CCR-10-2076 ↗
23. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma10.1016/j.ophtha.2009.10.015 ↗
24. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model10.1016/j.jconrel.2019.03.010 ↗
25. Souto, E.B., Souto, S.B., Campos, J.R., Severino, P., Pashirova, T.N., Zakharova, L.Y., Silva, A.M., Durazzo, A., Lucarini, M., and Izzo, A.A. (2019). Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. Molecules, 24.10.3390/molecules24234209 ↗
26. Vascular endothelial growth factor and angiogenesis10.1124/pr.56.4.3 ↗
27. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor–positive human tumors10.1182/blood.V98.6.1904 ↗
28. Vascular endothelial growth factor as a target for anticancer therapy10.1634/theoncologist.9-suppl_1-2 ↗
29. VEGF-targeted therapy: Mechanisms of anti-tumour activity10.1038/nrc2403 ↗
30. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers10.1200/JCO.2012.46.3653 ↗
31. Normalization of the vasculature for treatment of cancer and other diseases10.1152/physrev.00038.2010 ↗
32. Totzeck, M., Hendgen-Cotta, U.B., Kelm, M., and Rassaf, T. (2014). Crosstalk between nitrite, myoglobin and reactive oxygen species to regulate vasodilation under hypoxia. PLoS ONE, 9.10.1371/journal.pone.0105951 ↗
33. Hypoxia: A key regulator of angiogenesis in cancer10.1007/s10555-007-9066-y ↗
34. Hypoxia-Inducible Factor-1 Mediates Activation of Cultured Vascular Endothelial Cells by Inducing Multiple Angiogenic Factors10.1161/01.RES.0000093984.48643.D7 ↗
35. Matrix Metalloproteinases: Inflammatory Regulators of Cell Behaviors in Vascular Formation and Remodeling10.1155/2013/928315 ↗
36. Pericytes and ocular diseases10.1016/j.exer.2007.10.013 ↗
37. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression10.1038/nm0295-149 ↗
38. Further characterization of malignant glioma-derived vascular permeability factor10.3171/jns.1988.69.2.0254 ↗
39. The biology of VEGF and its receptors10.1038/nm0603-669 ↗
40. Anti-angiogenic therapy in uveal melanoma10.1159/000329591 ↗
41. Vieira, R., Souto, S.B., Sanchez-Lopez, E., Machado, A.L., Severino, P., Jose, S., Santini, A., Silva, A.M., Fortuna, A., and Garcia, M.L. (2019). Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II. J. Clin. Med., 8.10.3390/jcm8091332 ↗
42. Vieira, R., Souto, S.B., Sanchez-Lopez, E., Machado, A.L., Severino, P., Jose, S., Santini, A., Fortuna, A., Garcia, M.L., and Silva, A.M. (2019). Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I. Pharmaceuticals (Basel), 12.10.3390/ph12040152 ↗
43. Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)10.1007/s00228-011-1038-z ↗
44. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies10.1038/nrendo.2016.105 ↗
45. WHO (2018). Global Reports on Diabetes, World Health Organization. Available online: http://www.who.int.org.
46. A decade of nutraceutical patents: Where are we now in 2018?10.1080/13543776.2018.1552260 ↗
47. Santini, A., and Novellino, E. (2017). To Nutraceuticals and Back: Rethinking a Concept. Foods, 6.10.3390/foods6090074 ↗
48. Nutraceuticals—Shedding light on the grey area between pharmaceuticals and food10.1080/17512433.2018.1464911 ↗
49. From pharmaceuticals to nutraceuticals: Bridging disease prevention and management10.1080/17512433.2019.1552135 ↗
50. Polyphenols: A concise overview on the chemistry, occurrence, and human health10.1002/ptr.6419 ↗
51. Durazzo, A., D’Addezio, L., Camilli, E., Piccinelli, R., Turrini, A., Marletta, L., Marconi, S., Lucarini, M., Lisciani, S., and Gabrielli, P. (2018). From Plant Compounds to Botanicals and Back: A Current Snapshot. Molecules, 23.10.3390/molecules23081844 ↗
52. Durazzo, A., Lucarini, M., Novellino, E., Souto, E.B., Daliu, P., and Santini, A. (2018). Abelmoschus esculentus (L.): Bioactive Components’ Beneficial Properties-Focused on Antidiabetic Role-For Sustainable Health Applications. Molecules, 24.10.3390/molecules24010038 ↗
53. Abscisic acid identification in Okra, Abelmoschus esculentus L. (Moench): Perspective nutraceutical use for the treatment of diabetes10.1080/14786419.2019.1637874 ↗
54. Salehi, B., Ata, A., Anil Kumar, V.N., Sharopov, F., Ramírez-Alarcón, K., Ruiz-Ortega, A., Abdulmajid Ayatollahi, S., Tsouh Fokou, P.V., Kobarfard, F., and Amiruddin Zakaria, Z. (2019). Antidiabetic potential of medicinal plants and their active components. Biomolecules, 9, (in press).10.3390/biom9100551 ↗
55. Diabetic retinopathy and systemic factors10.4103/0974-9233.154388 ↗
56. Diabetic retinopathy: A comprehensive review10.4103/0019-5359.48562 ↗
57. Zhang, W., Liu, H., Al-Shabrawey, M., Caldwell, R.W., and Caldwell, R.B. (2011). Inflammation and Diabetic Retinal Microvascular Complications, Elsevier.10.4103/0975-3583.83035 ↗
58. The natural history of diabetic retinopathy
59. Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review
60. Early cellular and molecular changes induced by diabetes in the retina10.1007/s001250100544 ↗
61. Retinal neurodegeneration: Early pathology in diabetes10.1046/j.1442-9071.2000.00222.x ↗
62. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin10.1172/JCI2425 ↗
63. Retinal ganglion cells in diabetes10.1113/jphysiol.2008.156695 ↗
64. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina10.1007/s00125-003-1177-6 ↗
65. Pathologic alterations of the outer retina in streptozotocin-induced diabetes10.1167/iovs.13-13562 ↗
66. Decreased rhodopsin regeneration in diabetic mouse eyes
67. Müller cell changes in human diabetic retinopathy10.2337/diabetes.47.3.445 ↗
68. Expression of apoptosis markers in the retinas of human subjects with diabetes10.1167/iovs.03-1392 ↗
69. Microglia activation in retinal degeneration10.1189/jlb.0207114 ↗
70. Mechanisms of Retinal Fluid Accumulation and Blood-Retinal Barrier Breakdown10.1159/000455265 ↗
71. Diabetic retinopathy: Breaking the barrier10.1016/j.pathophys.2017.07.001 ↗
72. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient10.1155/2007/61038 ↗
73. Progressive proliferative diabetic retinopathy after transplantation of the pancreas10.1111/j.1755-3768.1994.tb04693.x ↗
74. Advanced protein glycosylation in diabetes and aging10.1146/annurev.med.46.1.223 ↗
75. Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies10.1172/jci.insight.93751 ↗
76. Diabetic retinopathy: Hyperglycaemia, oxidative stress and beyond10.1007/s00125-017-4435-8 ↗
77. Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) Axis in the Pathogenesis of Diabetic Retinopathy
78. emerging evidence of epigenetic Modifications in vascular Complication of Diabetes10.3389/fendo.2017.00237 ↗
79. Diabetic retinopathy, metabolic memory and epigenetic modifications10.1016/j.visres.2017.02.011 ↗
80. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)10.1136/bjo.2007.129122 ↗
81. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema10.1016/j.ajo.2007.12.031 ↗
82. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)10.1016/S0002-9440(10)65044-4 ↗
83. Novel pharmacotherapies in diabetic retinopathy: Current status and what’s in the horizon?10.4103/0301-4738.178154 ↗
84. The PKCβ/HuR/VEGF pathway in diabetic retinopathy10.1016/j.bcp.2010.06.033 ↗
85. Role of phospholipases A2 in diabetic retinopathy: In vitro and in vivo studies10.1016/j.bcp.2013.09.008 ↗
86. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat10.1016/j.phrs.2016.07.042 ↗
87. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress10.1161/01.CIR.0000034509.14906.AE ↗
88. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated10.2337/diacare.19.11.1306b ↗
89. Vitreous mediators in retinal hypoxic diseases
90. Vascular endothelial growth factor and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives10.1002/dmrr.415 ↗
91. Retinal pigment epithelium-secretome: A diabetic retinopathy perspective10.1016/j.cyto.2017.02.013 ↗
92. Association of vitreous inflammatory factors with diabetic macular edema10.1016/j.ophtha.2008.09.037 ↗
93. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection10.1097/IAE.0000000000000535 ↗
94. Rangasamy, S., McGuire, P.G., Nitta, C.F., Monickaraj, F., Oruganti, S.R., and Das, A. (2014). Chemokine mediated monocyte trafficking into the retina: Role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS ONE, 9.10.1371/journal.pone.0108508 ↗
95. TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis10.1167/iovs.10-5768 ↗
96. Infliximab for diabetic macular edema refractory to laser photocoagulation: A randomized, double-blind, placebo-controlled, crossover, 32-week study10.2337/dc09-2372 ↗
97. Interleukin 6 induces the expression of vascular endothelial growth factor10.1074/jbc.271.2.736 ↗
98. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy10.3129/i06-070 ↗
99. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients10.1007/s00417-004-0950-7 ↗
100. Diabetic retinopathy: Vascular and inflammatory disease10.1155/2015/582060 ↗